IDEAYA Biosciences Inc (IDYA) Stock Analysis

Verdict: HOLD

Strong cash runway and high-tier pharma partnerships mitigate clinical binary risk; Roche collaboration serves as a 90-day sentiment floor.

Investment score: 64/100

Analysis as of 2026-06-08

Is IDEAYA Biosciences Inc stock worth reviewing? The TradeMates thesis

IDEAYA is a well-capitalized precision oncology firm with a de-risked balance sheet and high-quality partnerships (Roche, GSK) that provide a floor for valuation.

7-factor investment score

Valuation: 55/100 (weight 20%)
Financial Health: 85/100 (weight 15%)
Technical Momentum: 60/100 (weight 15%)
Earnings Quality: 50/100 (weight 15%)
Insider Sentiment: 75/100 (weight 10%)
Analyst Consensus: 90/100 (weight 10%)
Risk-Adjusted Return: 45/100 (weight 15%)

IDEAYA Biosciences Inc opportunities and risks

What speaks for IDYA

Roche Collaboration for IDE892 (PRMT5)

What speaks against IDYA

Clinical Trial Binary Risk

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
IDYA	n/a	12.3x	n/a	99.5%	-62.2%	-3.2%
RLAY	n/a	223.9x	n/a	89.7%	-2554.1%	-8.9%
RCUS	n/a	9.9x	n/a	97.0%	-156.4%	-20.8%
DYN	n/a	0.0x	n/a	0.0%	0.0%	-16.6%
ARQT	n/a	6.5x	209.2x	90.9%	-0.6%	1.0%
GRAL	n/a	16.9x	n/a	-14.8%	-253.2%	-11.0%
Peer median	n/a	9.9x	n/a	89.7%	-156.4%	-11.0%

Frequently asked questions about IDEAYA Biosciences Inc (IDYA)

Is IDYA stock a good investment?

The TradeMates model rates IDEAYA Biosciences Inc as HOLD with an investment score of 64/100. IDEAYA is a well-capitalized precision oncology firm with a de-risked balance sheet and high-quality partnerships (Roche, GSK) that provide a floor for valuation. This is algorithmic model output, not personal investment advice.

Is IDYA stock a buy?

The TradeMates model verdict for IDYA is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.